7CA Stock Chart & Stats
€53.40
-€0.75(-1.33%)
At close: 4:00 PM EDT
€53.40
-€0.75(-1.33%)
Day’s Range― - ―
52-Week Range€40.60 - €67.15
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€3.53B
Enterprise Value€29.70B
Total Cash (Recent Filing)€4.07B
Total Debt (Recent Filing)€108.40M
Price to Earnings (P/E)58.3
Beta0.85
Next Earnings
Nov 05, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.39
Shares Outstanding60,559,185
10 Day Avg. Volume26
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€77.79Price Target Upside45.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.35
Revenue Forecast (FY)€254.88M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthGrowth is supported by expanding patient treatment and stronger royalty flows, not just a single product shipment. Buvidal’s increasing adoption and Brixadi’s U.S. momentum can reinforce recurring revenue, improve commercial scale, and support continued expansion over the next several quarters.
Profitability And Balance SheetExceptional margins indicate substantial economic value from Camurus’s products and technology, while very low leverage limits financial risk. The combination of profitability and a conservative balance sheet gives management flexibility to fund launches, research, and regulatory work without relying heavily on external financing.
Pipeline And Technology ValidationMultiple clinical and partnership catalysts diversify the company beyond its established opioid-dependence products. Progress in long-acting formulations and Lilly’s expanded collaboration provide evidence that FluidCrystal has broader commercial potential, supporting future product and royalty opportunities.
Bears Say
U.S. Regulatory TimingThe Complete Response Letter delays the U.S. approval pathway for CAM2029 and creates dependence on remediation acceptance and a likely follow-up inspection. Even though the issue was not linked to efficacy or safety, uncertain timing can defer commercialization, revenue contribution, and return on development investment.
Cash-flow Momentum And Investment SpendingAbsolute cash generation remains healthy, but declining free cash flow and higher working-capital needs reduce near-term conversion of earnings into available cash. Planned commercial and R&D spending may support growth, yet it also increases execution demands and can temporarily constrain financial flexibility.
Australian Capacity ConstraintsPatient and clinic capacity constraints can limit prescription growth even when underlying demand for long-acting treatment is attractive. This makes the Australian contribution less predictable over the next several months and may delay the benefit of potential patient transfers following a competitor’s withdrawal.
Camurus AB News
7CA FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was €40.60 and its highest was €67.15 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is €3.53B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Jul 15, 2026. The company reported €0.365 earnings per share for the quarter, beating the consensus estimate of €0.29 by €0.075.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 0.34.
How many shares outstanding does Camurus AB have?
Camurus AB has 60,559,185 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of €0.365 in its last earnings report, beating expectations of €0.29. Following the earnings report the stock price went up 10.938%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in DE:7CA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
7CA Company Deck
7CA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive commercial and financial picture: record product sales, broad‑based Buvidal growth, accelerating U.S. Brixadi royalties, improving underlying revenue CAGR (~21%), strong profitability (42% margin) and a robust cash position (SEK 4.1 billion). Pipeline momentum is substantial with SORENTO nearing primary analysis, CAM2056 advancing, positive POSITANO data and an expanded Lilly collaboration. Key negatives center on a manufacturing‑related FDA Complete Response Letter for the U.S. CAM2029 filing, short‑term working capital and investment outflows, increased SG&A as commercial scale‑up continues, and market/capacity constraints in Australia. Overall, the positives (record sales, revenue growth, strong cash and multiple near‑term pipeline catalysts) outweigh the material but addressable regulatory and operational risks.View all DE:7CA earnings summaries7CA Stock 12 Month Forecast
Average Price Target
€77.79
▲(45.67% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―